Role of teriparatide in fracture healing: A prospective study

Dr. Hrushikesh R Saraf and Dr. Shreepal Munot

DOI: http://dx.doi.org/10.22271/ortho.2017.v3.i3g.74

Abstract

Background: The biology of bone repair and healing is interesting and a huge number of studies have been done in this aspect with the potential technologies for enhancing fracture-healing. Teriparatide an anabolic agent a recombinant parathyroid hormone preparation that activates osteoblastic bone formation has been used in the treatment of postmenopausal osteoporosis. It has also been reported to be effective in accelerating the rate of fracture healing. The conclusion that PTH as an effective anabolic therapy for the enhancement of bone repair after fracture has been studied in animals and very few case studies. This prospective study was conducted to determine and establish the role of recombinant teriparatide in fracture healing in delayed union fractures, osteoporotic fractures, periprosthetic fractures.

Materials and Methods: The study was done on 20 patients with fractures selected on the basis of inclusion and exclusion criteria at Shashwat hospital, Pune during the period of September 2011 to September 2015. All patients were administered 20ug of teriparatide injections daily. The injections were given for 2 - 4 months depending on type of fracture and the time required for radiological evidence of union. Radiographs were taken every 4 weeks to see for callus and fracture union. The primary endpoint of fracture healing was taken as the time of cortical bridging in three of four cortices.

Results: The fractures treated with 20ug of teriparatide exhibited early signs of union with abundant callus formation significant decrease in radiological union time and early rehabilitation of patients in all three groups.

Conclusions: This study shows that the daily systemic administration of recombinant teriparatide enhances fracture-healing by increasing bone mineral content, density and strength. It also produces a sustained anabolic effect throughout the remodeling phase of fracture-healing. It also emphasizes that teriparatide is a relatively safe drug. Economical compared to other options of fracture healing like bone grafting, second surgery and is less invasive and has better patient compliance.

Keywords: Teriparatide, fracture healing, callus, delayed union, periprosthetic, osteoporotic fractures

Introduction

Bone healing after a fracture is a special form of wound-healing. The bone regenerates rapidly and heals without a scar. The three stages of bone repair are: inflammatory (haematoma formation with induction of inflammation), reparative (callus formation with stabilization), and remodeling (balancing and returning to its near normal structure). When a bone is injured and sustains a fracture there is a release of inflammatory cells which cause the release of many variety of substances which include TNFa, growth factors,VEGF,IL-3/6, fibronectin, histamine, fibroblasts, endothelial cells, osteoblasts and many more which all in conjecture help fill the void at the fracture site with inflammatory tissue. The second stage which is the reparative phase begins at about 2 weeks and involves a peristeaal response with new blood vessel formation for the new bone and cells to survive and nourishment. This leads to the stabilization of the fracture site with the formation of connective tissue and soft callus, which is gradually turned into immature woven bone via intramembranous or endochondral bone formation. The final stage is the remodeling phase where the woven bone callus is eventually replaced by lamellar bone. In many cases the fracture healing is by endochondral bone formation pathway, but an intervention with a rigid fixation can lead to a primary cortical repair. In course of time the fracture undergoes osteoclast-mediated remodeling which leads to the restoration of its original geometry and structural integrity. Despite this inherent complex and co-ordinated nature of the repair process, many patients still require a longer duration of
time before a fracture is completely healed and returns to its original indentity. This has promoted keen interests in the biology and its modifications in treatments that could stimulate and increase the rate of fracture healing and repair, providing decreased morbidity and an early return to an active lifestyle and work.

This fracture healing is assisted by many biological agents, one of them being the parathyroid hormone. Biochemically parathyroid hormone (PTH) is a protein polypeptide made up of amino-acids. It is a key regulator in the calcium and phosphate metabolism. The principal effect of PTH in the metabolism and maintaining the bone mineral equilibrium are to increase serum calcium levels which is by increasing the gastrointestinal calcium absorption, increases renal calcium and phosphate reabsorption, activates osteoclasts to release calcium from the skeleton in response to hypocalcemia, and play a role in the regulation of vitamin-D metabolism. The principal effect of PTH in the regulation of amino-acids. It is a key regulator in the calcium and metabolism. The PTH fragment of the bone's calcium balance is beneficial in the treatment of fracture healing.

This fracture healing is assisted by many biological agents, one of them being the parathyroid hormone. Biochemically parathyroid hormone (PTH) is a protein polypeptide made up of amino-acids. It is a key regulator in the calcium and phosphate metabolism. The principal effect of PTH in the metabolism and maintaining the bone mineral equilibrium are to increase serum calcium levels which is by increasing the gastrointestinal calcium absorption, increases renal calcium and phosphate reabsorption, activates osteoclasts to release calcium from the skeleton in response to hypocalcemia, and play a role in the regulation of vitamin-D metabolism. The principal effect of PTH in the regulation of amino-acids. It is a key regulator in the calcium and metabolism. The PTH fragment of the bone's calcium balance is beneficial in the treatment of fracture healing.

Materials and methods
The study was done on 20 patients with fractures selected on the basis of inclusion and exclusion criteria at Shaswat hospital, Pune during the period of September 2011 to September 2015. This study included both male and female patients.

Inclusion criteria were patients with 1) age more than 25 years 2) delayed union 3) periprosthetic fractures 4) osteoporotic fractures. Exclusion criteria were 1) Age less than 25 years 2) Compound fractures 3) Associated significant systemic comorbid illnesss 4) History of tumor or chemotherapy, bone metastases, metabolic bone disease, rheumatoid arthritis, chronic renal failure 5) pregnant and lactating women.

The patients which satisfied the inclusion criteria were selected and on arrival at the hospital detailed history and clinical examination was done. Routine blood investigations like CBC, ESR, RFT, RBS were done. Concomitant morbidities were addressed and specific treatment given. X-rays were taken before starting the injection in at least two views preferably AP and Lateral views.

Materials and methods
The study was done on 20 patients with fractures selected on the basis of inclusion and exclusion criteria at Shaswat hospital, Pune during the period of September 2011 to September 2015. This study included both male and female patients.

Inclusion criteria were patients with 1) age more than 25 years 2) delayed union 3) periprosthetic fractures 4) osteoporotic fractures. Exclusion criteria were 1) Age less than 25 years 2) Compound fractures 3) Associated significant systemic comorbid illnesss 4) History of tumor or chemotherapy, bone metastases, metabolic bone disease, rheumatoid arthritis, chronic renal failure 5) pregnant and lactating women.

The patients which satisfied the inclusion criteria were selected and on arrival at the hospital detailed history and clinical examination was done. Routine blood investigations like CBC, ESR, RFT, RBS were done. Concomitant morbidities were addressed and specific treatment given. X-rays were taken before starting the injection in at least two views preferably AP and Lateral views.

Materials and methods
The study was done on 20 patients with fractures selected on the basis of inclusion and exclusion criteria at Shaswat hospital, Pune during the period of September 2011 to September 2015. This study included both male and female patients.

Inclusion criteria were patients with 1) age more than 25 years 2) delayed union 3) periprosthetic fractures 4) osteoporotic fractures. Exclusion criteria were 1) Age less than 25 years 2) Compound fractures 3) Associated significant systemic comorbid illnesss 4) History of tumor or chemotherapy, bone metastases, metabolic bone disease, rheumatoid arthritis, chronic renal failure 5) pregnant and lactating women.

The patients which satisfied the inclusion criteria were selected and on arrival at the hospital detailed history and clinical examination was done. Routine blood investigations like CBC, ESR, RFT, RBS were done. Concomitant morbidities were addressed and specific treatment given. X-rays were taken before starting the injection in at least two views preferably AP and Lateral views.

Materials and methods
The study was done on 20 patients with fractures selected on the basis of inclusion and exclusion criteria at Shaswat hospital, Pune during the period of September 2011 to September 2015. This study included both male and female patients.

Inclusion criteria were patients with 1) age more than 25 years 2) delayed union 3) periprosthetic fractures 4) osteoporotic fractures. Exclusion criteria were 1) Age less than 25 years 2) Compound fractures 3) Associated significant systemic comorbid illnesss 4) History of tumor or chemotherapy, bone metastases, metabolic bone disease, rheumatoid arthritis, chronic renal failure 5) pregnant and lactating women.

The patients which satisfied the inclusion criteria were selected and on arrival at the hospital detailed history and clinical examination was done. Routine blood investigations like CBC, ESR, RFT, RBS were done. Concomitant morbidities were addressed and specific treatment given. X-rays were taken before starting the injection in at least two views preferably AP and Lateral views.

Materials and methods
The study was done on 20 patients with fractures selected on the basis of inclusion and exclusion criteria at Shaswat hospital, Pune during the period of September 2011 to September 2015. This study included both male and female patients.

Inclusion criteria were patients with 1) age more than 25 years 2) delayed union 3) periprosthetic fractures 4) osteoporotic fractures. Exclusion criteria were 1) Age less than 25 years 2) Compound fractures 3) Associated significant systemic comorbid illnesss 4) History of tumor or chemotherapy, bone metastases, metabolic bone disease, rheumatoid arthritis, chronic renal failure 5) pregnant and lactating women.
Results
A total of 20 patients with 20 fractures treated were evaluated in this study (Table 1). The mean age of the patients were 60.7 years (delayed union 48.42 years, osteoporotic 76 years, periprosthetic group 57.16 years) and ranged from 40-83 years. A total of 10 males (50%) and 10 females (50%) were involved. Fractures involving various anatomical sites were evaluated. Fracture sites included humerus, radius, wrist, femur, tibia, and ankle. A total of 20 patients had daily injection of subcutaneous teriparatide. All of the patients were administered 20μg of teriparatide. The signs of healing were seen in all the patients at 3-4 weeks. The mean dosage of teriparatide injection time was 12.6 weeks. The minimum duration was 10 and the maximum duration was 16 weeks. We analysed the efficacy of teriparatide via radiological outcome. Radiological findings involved the use of X-rays to assess for callus formation, bony bridging, reduction of fracture line and complete bony union. The mean time to bony bridging after starting PTH (1-34) varied widely across different fracture groups. (table 2) For delayed union fractures, administration of teriparatide was associated with a mean time to bony bridging of 12 weeks. For periprosthetic fractures the average healing time was 12.6 weeks.13.2 weeks for osteoporotic fracture group.

A total of 6 patients experienced mild side effect from teriparatide administration. 1 patients complained of dizziness while 3 patients reported mild side effects such as nausea, vomiting and 2 patients reported to have leg cramps. No other side effects were noted from the studies involving teriparatide administration. none of the side effects were significant to cause discontinuation of teriparatide.

**Table 1**

<table>
<thead>
<tr>
<th>S. No.</th>
<th>Id</th>
<th>Age</th>
<th>Sex</th>
<th>Diagnosis</th>
<th>When teriparatide Started</th>
<th>Duration of injection (in weeks)</th>
<th>Upper limb (ul)/ Lower limb (ll)</th>
<th>Comobrid</th>
<th>Complication</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>47</td>
<td>M</td>
<td>Delayed Union</td>
<td>16 weeks</td>
<td>14</td>
<td>LL</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>78</td>
<td>F</td>
<td>Osteoporotic #</td>
<td>Immediately</td>
<td>16</td>
<td>LL</td>
<td>DM</td>
<td>Nausea</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>70</td>
<td>M</td>
<td>Periprosthetic #</td>
<td>Immediately</td>
<td>13</td>
<td>LL</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>50</td>
<td>M</td>
<td>Osteoporotic #</td>
<td>Immediately</td>
<td>12</td>
<td>LL</td>
<td>HTN</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>72</td>
<td>M</td>
<td>Osteoporotic #</td>
<td>Immediately</td>
<td>12</td>
<td>UL</td>
<td>HTN</td>
<td>Cramps</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>75</td>
<td>F</td>
<td>Osteoporotic #</td>
<td>Immediately</td>
<td>13</td>
<td>UL</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>42</td>
<td>M</td>
<td>Delayed Union</td>
<td>24 weeks</td>
<td>12</td>
<td>LL</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>52</td>
<td>M</td>
<td>Delayed Union</td>
<td>24 weeks</td>
<td>10</td>
<td>LL</td>
<td>-</td>
<td>Cramps</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>58</td>
<td>F</td>
<td>Delayed Union</td>
<td>22 weeks</td>
<td>11</td>
<td>UL</td>
<td>HTN</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>52</td>
<td>M</td>
<td>Periprosthetic #</td>
<td>Immediately</td>
<td>14</td>
<td>UL</td>
<td>-</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>70</td>
<td>F</td>
<td>Osteoporotic #</td>
<td>Immediately</td>
<td>14</td>
<td>LL</td>
<td>DM/HTN</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>75</td>
<td>F</td>
<td>Osteoporotic #</td>
<td>Immediately</td>
<td>12</td>
<td>LL</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>40</td>
<td>M</td>
<td>Delayed Union</td>
<td>26 weeks</td>
<td>14</td>
<td>UL</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>60</td>
<td>M</td>
<td>Delayed Union</td>
<td>21 weeks</td>
<td>11</td>
<td>UL</td>
<td>-</td>
<td>Dizziness</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>40</td>
<td>F</td>
<td>Delayed Union</td>
<td>25 weeks</td>
<td>12</td>
<td>LL</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>60</td>
<td>M</td>
<td>Periprosthetic #</td>
<td>Immediately</td>
<td>10</td>
<td>UL</td>
<td>HTN</td>
<td>Nausea</td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>65</td>
<td>F</td>
<td>Periprosthetic #</td>
<td>Immediately</td>
<td>12</td>
<td>UL</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>56</td>
<td>M</td>
<td>Periprosthetic #</td>
<td>Immediately</td>
<td>14</td>
<td>LL</td>
<td>-</td>
<td>Nausea</td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>60</td>
<td>F</td>
<td>Periprosthetic #</td>
<td>Immediately</td>
<td>13</td>
<td>LL</td>
<td>HTN</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>83</td>
<td>F</td>
<td>Osteoporotic #</td>
<td>Immediately</td>
<td>14</td>
<td>LL</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
</tbody>
</table>

**Table 2**

<table>
<thead>
<tr>
<th>Group</th>
<th>No of patients</th>
<th>Age</th>
<th>Injection Started</th>
<th>Weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Osteoporotic</td>
<td>7</td>
<td>76</td>
<td>Immediately</td>
<td>13.2 weeks</td>
</tr>
<tr>
<td>Delayed Union</td>
<td>7</td>
<td>48.42</td>
<td>22.57 weeks</td>
<td>12 weeks</td>
</tr>
<tr>
<td>Periprosthetic Fracture</td>
<td>6</td>
<td>57.16</td>
<td>Immediately</td>
<td>12.6 weeks</td>
</tr>
</tbody>
</table>
Case 2
Age: 78 yrs/F
Bilateral osteoarthritis knee for which bilateral TKR done 4 years back

Pre op x-ray

Post op x-ray

4 weeks post op
12 weeks post op
24 weeks follow up

After 3 months of therapy
After implant removal
6 month back she had history of fall injury to right knee comminuted fracture and papery thin fracture fragments

ORIF with locking plate and screw

12 weeks after teriparatide inj 16 weeks after teriparatide inj...
Discussion
Fracture healing is considered as a very complex process that involves the coupled effect of resorption and formation. For elderly osteoporotic subjects, the bone is ductile, weak and undergoes plastic deformation well before fragility breaks can occur. The main action of the synthetic molecule teriparatide is to enhance and stimulate bone formation which is by increasing the osteoblastic activity. It does not stimulate bone resorption. This is known as the “anabolic window.” There a number of mechanisms for teriparatide to facilitate fracture healing, which include promoting proliferation and differentiation of mesenchymal stem cell, chondroprogenitors and osteoprogenitors, chondrocyte maturation, production of bone matrix proteins, and formation of osteoclasts. In the course of fracture healing, it can promote callus formation by incorporating and stimulating the proliferation and differentiation of osteoprogenitors and chondroprogenitors [36, 37]. It also promotes the early callus formation and callus remodeling by stimulating matrix proteins for the bones and formation of osteoclasts [37]. The Wnt/β-catenin signaling pathway which regulates the type II and X collagen involved in determining the size of the callus is also promoted and enhanced by the administration of teriparatide [38].

The effect of Teriparatide on fracture healing has been shown to be beneficial. Some of the literature and recent papers on the effect of teriparatide in primary union, delayed and non-union have resulted in enhancement in the time to clinical and radiological union. Chintamaneni et al. (2010) noted that the dramatic radiographic healing of a non-union fracture was achieved only after intervention with teriparatide (Chintamaneni et al., 2010). One of the study analysed the effects of PTH (1-84) on fracture healing in 65 postmenopausal women with osteoporosis who had sustained a pelvic fracture. Although the PTH compound used was different (PTH 1-84 vs. PTH 1-34), the additional fifty amino acids in PTH 1-84 are inactive and the resulting bio-efficacy of the two compounds remain the same. Both are known to have similar anabolic effects and the resulting bio-efficacy of the two compounds remain the same. Both are known to have similar anabolic effects although there is currently a paucity of comparative studies between the two (Verhaar and Lems, 2009). Peichl et al. (2011) found that administration of PTH 1-84 (100 μg day-1) resulted in a shorter fracture union time in primary union compared to a control group (Peichl et al., 2011). Pubic bone fracture treated with PTH 1-84 achieved fracture union in 7.8 weeks compared to 12.6 weeks a control group (p<.001). By eight weeks all fractures in the treatment group (n = 21) had healed in contrast to 4 fractures in the control group (n = 44). (Healing rate, 100% [95% CI, 86.7-100.0%] compared with 9.1% [95% CI, 2.5-21.7%]). The treatment group also had statistically significant improved clinical and functional outcomes (p<0.001) as compared to the control group (assessed with both visual analogue scale for pain and a timed up and go test).

In another prospective randomized double-blind clinical study by Aspenberg et al. (2010) the use of teriparatide (PTH 1-34) resulted in shorter time to fracture healing in conservatively treated distal radial fractures (Aspenberg et al., 2010). Time to healing was significantly shorter in the treatment group (n = 34) that received teriparatide 20 μg day-1 (7.4 weeks, p = 0.006) as compared to the control group (9.1 weeks, n = 34). Surprisingly, the study acknowledges a lack of dose response relationship with intermittent administration of PTH 1-34. The treatment group (n = 34) that received teriparatide 40 μg day-1 showed shorter healing time compared to the control group. Youngwoo Kim et al. studied effect of teriparatide in femoral shaft fractures showed that the callus formation after teriparatide therapy was approximately 2 weeks more early than normal healing. Moreover, this callus formation progressed for 8 weeks and led to healing of the fracture. In delayed unions the treatment of choice is bone grafting but this procedure is not without complications of the fracture site as well the donor site morbidity. In our study we see that union was achieved in such fractures with only the use of teriparatide.

Teriparatide also is useful in the management of hypophosphathemic patients. These patients who have defective bone mineralization are benefitted by treatment with teriparatide.

The safety profile of Teriparatide continues to be excellent with only 8 of patients experiencing mild side effects ranging from nausea, vomiting and headache. In the study by Peichl et al. (2011) no adverse events or death were recorded among the 21 patients who took PTH 1-84 for 24 months (Peichl et al., 2011). The long-term safety profile of teriparatide is however still unknown. The anabolic effects of teriparatide when given long-term and in supra-physiological doses were associated with an increased risk of osteosarcomas in Fisher rats (Vahle et al., 2002). This risk is negated by the use of smaller doses in humans and is somewhat comparable to the general population risk, where only 1 case of osteosarcoma has been reported (Harper et al., 2007) among more than 250,000-300,000 patients treated with teriparatide worldwide (Solomon et al., 2009). Due to this risk profile of the hormone its use is cautioned in patients with significant history of primary or metastatic bone tumours, Paget’s disease, unexplained high levels of ALP, history of radiation therapy involving the bones or metabolic bone disease excluding osteoporosis, pregnancy and breast feeding (Guide et al., 2002). Some of the other side effects of teriparatide include dizziness, constipation, lethargy, muscle weakness and cramping in the legs which is due to raised serum calcium levels.

The local side effects at the site of injection include erythema, swelling, itch and pain. Teriparatide also can raise the serum levels.
Clinical indications for the use of teriparatide in the treatment of fragility fractures in elderly patients. However, studies across this field are not much and some more clinical studies are needed to determine the usefulness of teriparatide and the clinical indications for the use of teriparatide in the treatment of fracture healing.

Conclusion
Teriparatide is a relatively safe drug with minimal adverse effects. Economical compared to other options of fracture healing like bone grafting, second surgery. Less invasive, more cost effective and better patient compliance. Enhances healing like bone grafting, second surgery. Less invasive, effects. Economical compared to other options of fracture healing.

Teriparatide is a relatively safe drug with minimal adverse effects. It can be used in fracture healing in patients with osteoporosis. Enhances the bone mineral density and prevents fragility fractures in elderly patients. However, studies across this field are not much and some more clinical studies are needed to determine the usefulness of teriparatide and the clinical indications for the use of teriparatide in the treatment of fracture healing.

References
24. Gabet Y, Kohavi D, Müller R et al. Intermittently administered parathyroid hormone 1-34 reverses bone uric acid levels and precaution has to be taken in patients with renal impairment. We acknowledge several limitations in our study. Considering that teriparatide has not commonly been used in fracture healing and its recent application for the same. The small sample size and the lack of control group were the other limitations.